Logo

The NMPA Accepts GenFleet Therapeutics’ NDA for GFH925 and Grants Priority Review for Lung Cancer

Share this
GenFleet

The NMPA Accepts GenFleet Therapeutics’ NDA for GFH925 and Grants Priority Review for Lung Cancer

Shots:

  • The CDE of the NMPA accepted GenFleet’s NDA for GFN925 and granted priority review based on the results from the P-II trial evaluating GFN925 as monotx. to treat advanced KRAS G12C-mutant NSCLC patients. The results from the trial are expected to be presented at ESMO Asia 2023
  • The P-I evaluation of GFH925 depicted that 41/67 NSCLC patients achieved a partial response with an ORR of 61.2% & DCR of 92.5% whereas in 30 NSCLC patients treated with RP2D (600mg, BID) an ORR & DCR of 66.7% & 96.7% was seen
  • GFN925, a KRAS G12C inhibitor, is being evaluated in China as a combination therapy by Innovent for NSCLC & is in P-II trial with Erbitux across Europe. Additionally, GFN925 has previously received a BTD by the NMPA for KRAS G12C mutant CRC

Ref: PR Newswire | Image: Genfleet

Related News:- Merck Entered into a Clinical Trial Collaboration with GenFleet Therapeutics to Initiate P-Ib/II Trial of GFH925 + Erbitux (cetuximab) for Non-small cell lung cancer

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Kritika Jha

Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions